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Abstract
Background: Postoperative bowel paralysis is common after abdominal operations, including colectomy. As a
result, hospitalization may be prolonged, thereby leading to increased cost. A recent randomized controlled trial
showed that the consumption of regular black coffee after colectomy is associated with a significantly faster
resumption of intestinal motility. The mechanism by which coffee stimulates intestinal motility is unknown, but
caffeine seems to be the most likely stimulating agent. Thus, the effect of caffeine on postoperative bowel activity
after colon surgery will be analyzed in this trial, herein referred to as CaCo.
Methods/design: Patients scheduled for elective laparoscopic colectomy or upper rectum resection are eligible to
participate in this double-blinded, placebo-controlled, randomized trial. Patients fulfilling all inclusion criteria will be
allocated after the surgical procedure to one of three treatment arms: 100 mg caffeine, 200 mg caffeine, or placebo
(corn starch). Patients will take the capsules containing the study medication three times daily with a meal. The
primary endpoint of the study is the time to a solid bowel movement. The study treatment will be stopped after
the patient produces a solid bowel movement or has taken ten capsules, whichever occurs first. To determine the
colonic passage time, patients will take a capsule with radiopaque markers at breakfast for the first 3 days after
surgery. On the fourth day, the location of the markers will be determined with an abdominal X-ray scan. Further
secondary objectives are the postoperative morbidity and mortality, well-being, sleeping behavior, and length of
hospital stay.
The study size was calculated to be 180 patients with an interim analysis occurring after 60 patients.
Discussion: From a previous study investigating coffee, evidence exists that caffeine might have a positive
influence on the postoperative bowel activity. This double-blinded, placebo-controlled, randomized trial tries to
show that caffeine will shorten the postoperative bowel paralysis and, thus, will improve recovery and shorten the
hospital stay after colon surgery.
Trial registration: Clinicaltrials.gov NCT02510911
Swiss National Clinical Trials Portal SNCTP000001131
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Background
Postoperative bowel paralysis is common after abdom-
inal operations, including colectomy [1]. In most pa-
tients, after colon resection, normal intestinal function
returns slowly. Surgical stress, pain, and bowel paralysis
contribute to this delay. A delay in bowel function (ileus)
may lead to a prolonged hospital stay, hospital-acquired
infections or complications, and pulmonary compromise
[1]. Patients with postoperative bowel paralysis have
symptoms of pain, distention, and emesis. They may
require treatments such as nasogastric tube, decom-
pression, analgesia, fluid, and electrolyte replacement.
Consequentially, hospitalization may be prolonged,
thereby leading to increased costs.
Because of the significant implications of bowel paraly-
sis after colectomy, surgeons have developed various
strategies to minimize postoperative bowel paralysis.
Multimodal approaches to treat postoperative bowel
paralysis in colorectal surgery include early feeding; the
restricted use of nasogastric tubes; thoracic epidural
analgesia; nonspecific pharmacologic agents, such as
water-soluble contrast agents (gastrografin); specific
agents, such as alvimopan; and a selective μ-receptor
opioid antagonist [1–5].
Chewing gum is another approach to stimulate bowel
function after surgery [6]. Asao et al. found an earlier
return of bowel function and a trend toward earlier
hospital discharge in patients who chewed gum after
laparoscopic colectomy. Gum is postulated to activate
the cephalic-vagal reflex, which is usually enhanced by
food, and to increase the production of the gastrointes-
tinal hormones associated with bowel motility [6].
Coffee is a popular beverage with well-known effects
on general well-being, the central nervous system, and
the cardiovascular system [7], but information is limited
regarding its effects on gastrointestinal function. The
gastrointestinal system can be stimulated by food with a
substantial caloric content, acidity, osmolality, or volume
load. Brewed and filtered coffee is hypotonic, as is water,
which serves as a control in most studies investigating
coffee. The hypotonicity of coffee, therefore, is unlikely
to be responsible for the effects on the gastrointestinal
tract. More likely, the ingredients of coffee have a
pharmacological effect on the gut.
Twenty-nine percent of a group of volunteers who an-
swered a questionnaire concerning their bowel habits
claimed that coffee induced a desire to defecate [8]. Rec-
tosigmoid motor responses to coffee were investigated
with a multiport manometry in these volunteers who
claimed that coffee caused a desire to defecate and in
volunteers who did not so claim. An increase in colonic
motor activity was found after 4 min of ingestion of both
regular and decaffeinated coffee in the responders but
not in the nonresponders. After water, no response in
any volunteer was found. Rao et al. performed an ambu-
latory manometry with a catheter positioned from the
rectum up to the midtransverse colon [9]. They studied
the effects of 240 ml of regular coffee, decaffeinated
coffee, water, and a 1000-kcal meal on colonic motil-
ity. Regular coffee, decaffeinated coffee, and the meal
induced more colonic activity and more propagated
contractions than water. Caffeinated coffee was concluded
to stimulate colonic motor activity at a magnitude com-
parable to a high-calorie meal, 60 % stronger than water,
and 25 % stronger than decaffeinated coffee.
A recently performed randomized controlled trial at
the University of Heidelberg showed that the consump-
tion of regular black coffee after colectomy is safe and is
associated with a significantly faster resumption of intes-
tinal motility [10]. Neither previous studies nor the study
from Heidelberg could clearly explain the mechanisms
by which coffee stimulates intestinal motility. The most
obvious stimulating agent would be caffeine. Therefore,
we would like to investigate the role of caffeine on bowel
motor activity in this study.
This study is restricted to laparoscopic colectomies
because colectomies are increasingly performed by this ac-
cess technique (our institution: 50–60 % of all colectomies
in 2014, German speaking countries: 25–30 %). Since the
time to bowel movement is significantly longer after open
surgery, open and laparoscopic approaches cannot be
compared without significant bias.
Methods/design
Study objectives
With this study, we would like to address whether caf-
feine has a beneficial effect on bowel paralysis after
colon resections and whether the side effects of caffeine
are within a tolerable range. If we can prove our as-
sumption, caffeine would be a very cost-effective drug to
treat postoperative bowel paralysis and could help to
shorten the length of the hospitalization.
Study design
This trial is a double-blinded, placebo-controlled, ran-
domized trial with three arms. Patients will be random-
ized after the surgical procedure to receive either 3 ×
100 mg caffeine, 3 × 200 mg caffeine, or 3 × 250 mg
corn starch (placebo) daily. Study participants will be
equally allocated to the three arms (1:1:1). The study is
an investigator-initiated trial, and the principal investiga-
tor also acts as the sponsor. The study will be performed
at two sites (St. Gallen and Rorschach) of a major, non-
academic, Swiss medical center. Both sites belong to the
same department of surgery.
The study protocol was drafted following the SPIRIT
statement (see Additional file 1 for a detailed SPIRIT
checklist).
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Outcomes
The primary outcome of the study will be the return to
normal bowel function after colon resection. The primary
endpoint will be the time to the first bowel movement
after surgery. Secondary objectives are the safety of the
caffeine treatment, particularly the degree and perception
of the known effects of caffeine, such as agitation and
insomnia, and the recovery from surgery, morbidity, and
mortality.
Study population
Study participants will be recruited from patients of the
Department of General, Visceral, Endocrine and Trans-
plantation Surgery scheduled for laparoscopic elective
colon and upper rectum resection. The indication for
surgery (oncologic or nononcologic) is not a selection
criterion.
In particular, the patient has to fulfill the following
criteria to be considered for study inclusion:
 The patient is scheduled for elective laparoscopic
colectomy (right or left hemicolectomy, segmental
resection, extended hemicolectomy, sigmoid
resection, or upper rectum (anastomosis higher than
7 cm above the anal verge)).
 The patient’s age is equal to or over 18 years old. As
long as the patient is fit for surgery, no upper age
limit exists.
 The patient gives informed consent before surgery.
The following criteria will exclude the patients from
trial participation:
 Participation in another concurrent interventional
trial
 Need for a stoma (colostomy or ileostomy) or
reversal of a stoma, if the patient had complete
bowel obstruction
 Known hypersensitivity or allergy to caffeine/coffee
 Expected lack of compliance (patient is notorious for
not following medical instructions, like taking
medications as prescribed, or following necessary
diets)
 American Society of Anesthesiologists (ASA)
Physical Status Score of IV or V
 Impaired mental state or language problems
 Alcoholism or drug abuse
 Previous extensive abdominal surgery (any open or
laparoscopic abdominal surgery except laparoscopic
appendectomy, cholecystectomy, or hernia repair)
 Inflammatory bowel disease
 Clinically significant cardiac arrhythmia (patient
suffers from physical complaints or is on regular
medication)
 Cardiac insufficiency (like the previous criterion as
safe guard against the effects of caffeine)
 Pregnancy, lactation, or childbearing potential
without using adequate contraception
 Intake of opioid analgesics, or steroids > 5 mg/day
for ≥ 7 days before surgery
 Under antidepressive medication
 Liver cirrhosis or compromised liver function
(MELD score > 15) (Caffeine is metabolized in liver
cells, and impaired liver function would result in a
prolonged half-life of the caffeine.)
The final decision to include (i.e., to randomize) the
patient in the trial will be made at the end of the surgery.
The following criteria have to be fulfilled:
 No major change of the planned surgery (like
conversion to open, unplanned placement of a
stoma, additional resections of adjacent organs, or
other major unplanned procedures)
 No epidural anesthesia used during or after surgery
Study withdrawal and stopping medication
After randomization, the patients can withdraw at any
time if they own wish without giving any reason.
Study treatment will be stopped for the following
reasons:
 Any adverse event resulting from surgery that might
interfere with the study drug or might lead to
meaningless endpoint data (e.g., organ failure,
anastomotic failure, or postoperative dementia). Due
to the complexities of postoperative morbidity, no
list of fixed criteria will be established. If such an
event occurs before the first study medication will
be taken, the patient will be withdrawn from the
study and replaced by another patient.
 Serious adverse events occur that are definitively or
probably related to the study drug.
 Tachycardia, defined as a pulse of over 120/min
three times within 1 hour, occurs.
 In the investigator’s opinion, continuation of the
treatment is detrimental to the patient’s well-being.
Unless the patient wishes to withdraw from the study,
all scheduled examinations will be performed as planned
as long as they are meaningful and do not pose an un-
necessary burden to the patient (e.g., no X-ray examin-
ation will be performed if treatment is stopped very
early or if the patient has multiple vomiting events dur-
ing the first 3 days postoperatively). Thus, stopping the
medication does not automatically constitute withdrawal
from the study.
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The investigator can withdraw a study patient if a
reoperation before the return to normal bowel function
is required, an epidural analgesia was placed, if there are
signs of renal insufficiency or an acute renal insufficiency,
or if the patient clearly is not compliant (repeated
refusal to take study medication or is consuming
caffeine-containing beverages or food).
Endpoints
The primary endpoint is the time to the first bowel
movement. The time will be measured from the time of
wound closure to the patient’s first bowel movement. Pa-
tients were advised before study participation to remem-
ber or note their first stool after surgery. A study nurse
will inquire daily whether bowel movement has occurred.
The definitions of the secondary endpoints are indi-
cated as follows. The time to tolerance of solid food is
measured from the end of surgery until the patient toler-
ates the intake of solid food. Tolerance of food is defined
as the first time the patient is able to eat solid food (any
food requiring chewing) without vomiting or experien-
cing significant nausea within 4 h after the meal and
without reversion to only enteral fluids.
Time to first flatus is the time from the end of surgery
until the patient’s first flatus. The passage of flatus will
be determined by questioning the patient; the passage of
a bowel movement will be determined by referring to
the nursing records or by the clinical judgment of the
investigator or designee following questioning of the
patient.
Postoperative vomiting events, determined from the
nursing records, refer to the number of times the patient
has to vomit.
Colonic passage time will be determined using ten
radiopaque markers (Colon Transit Radiopaque Markers,
P & A Mauch, 4142 Münchenstein, Switzerland, Ref:
CTT6V10, CE1253). From day 1 to day 3 after surgery,
the patients will receive one capsule with ten radiopaque
markers to be taken at breakfast. On day 4, a single ab-
dominal X-ray image (posterior-anterior) will be taken.
The colonic passage time in hours will be calculated
according to the following formula: colonic passage
time = the number of markers in the colon × 2.4 [11].
The number of each radiopaque marker in the stom-
ach, left colon, right colon, and rectosigmoid will be
recorded in a 3 × 4 table. Location of the organs on
the X-ray film will be done based on the gaseous out-
lines of the colon. If the organs are not discernible,
the method described by Metcalf et al. [11] will be
applied. Markers located to the right of the vertebral
spinous processes above a line from the fifth lumbar
vertebrae to the pelvic outlet are assigned to the right
colon. Markers to the left of the vertebral spinous
processes and above an imaginary line from the fifth
lumbar vertebrae to the anterior superior iliac crest are
assigned to the left colon. Markers inferior to a line from
the pelvic brim on the right and the superior iliac crest on
the left are judged to be in the rectosigmoid and rectum.
The postoperative hospital stay is the number of days
from surgery until discharge. Criteria for hospital dis-
charge include stable vital signs with no febrile morbid-
ity for at least 24 hours, passage of stool, toleration of a
regular diet, and the absence of other complications.
Swiss health insurance policies and social issues some-
times require longer hospitalization than medically
necessary. We will address this issue by recording the
medically indicated hospitalization along with the actual
hospitalization.
The time point when all the following criteria are met
will be used to calculate the medically indicated length
of hospitalization:
 Bowel movement
 Solid food is well tolerated
 No serious pain (no opioid containing medication
necessary)
 Unproblematic mobilization
 Surgical wound without signs of inflammation or
wound can be treated well in an outpatient setting
 Decreasing infectious/inflammatory parameters (on
day 4 after surgery CRP ≤ 135 mg/l, white blood
cells count ≤ 9 × 109/l) [12]
Postoperative pain will be recorded three times daily
using a numeric rating scale (NRS), with scores ranging
from 0 (= no pain at all) to 10 (= maximal pain) in in-
crements of 1. Additionally, the amount, type, and time
of application of analgesics will be obtained from the
medical and nursing records.
Postoperative mobilization will be documented for
1 week after surgery using the following categories:
0: 24 h in bed
1: Out of bed only to go to the bathroom
2: Out of bed on free will
The overall fluid intake will be taken from the nursing
records.
Blood pressure and pulse rate are recorded, usually
three times daily, during the routine visits.
The postoperative intensive care unit stay is the num-
ber of days in the intensive care unit. A stay in the re-
covery room exceeding 24 h is counted as an intensive
care unit stay.
Postoperative morbidity
The following set of predefined complications will be
considered as adverse events and documented:
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1. Anastomotic leakage: Communication between the
intraluminal and extraluminal compartments due to
a defect of the integrity of the intestinal wall at the
site of the anastomosis. Clinical findings suspicious
of leakage (i.e., abdominal pain, fever, elevated
infectious parameters, or feculent drain content)
must be confirmed by contrast-enhanced CT or
during relaparoscopy or laparotomy.
2. Postoperative hemorrhage: Any drop of hemoglobin >
3 g/dl (6 h after the end of surgery), any postoperative
transfusion of packed red blood cells for a falling
hemoglobin value, or hemorrhage requiring re-
intervention (i.e., embolization or laparotomy).
3. Intraabdominal fluid collection/abscess:
Intraabdominal fluid collection detected on any
imaging modality (e.g., ultrasound or CT scan)
associated with abdominal discomfort/pain or
elevation of infectious parameters.
4. Wound infection: Pain, redness, and swelling of the
wound that requires opening of the wound or
antibiotic therapy.
5. Pneumonia: Pulmonary infection with evidence of
increased infection parameters (CRP > 20 mg/l and/
or white blood cell count > 10 × 109/l) that are
unlikely to be caused by a different pathologic
process and evidence of pulmonary infiltrates on
chest X-ray, which require antibiotic therapy.
6. Mortality: Death due to any cause during the
patient’s initial hospital stay and within 30 days after
surgery (by calling the patient by phone).
7. Need for invasive re-intervention: Need for re-
laparoscopy, laparotomy, or other interventions (e.g.,
drainage) during the patient’s initial hospital stay.
Caffeine, nicotine, and sleeping habits evaluation
Before surgery, patients will be asked about their caffeine
and nicotine consumption and their sleeping behavior as
a reference for the following endpoints.
Well-being
No classical quality-of-life instruments (such as the SF36
or EORTC QLQ-C30) will be administered because
these usually cover periods of 14–28 days, which would
be too long for this study. In addition, no reason exists
to assume that the quality of life would differ between
the treatment and placebo group, statistically or clinic-
ally. Furthermore, a reference value would be difficult to
find, as the quality of life is certainly impaired before
surgery. Thus, well-being with respect to the mental
state will be measured for this study, which describes
the current mood and state of the patient. The Basel
Mental State Scale (Basler Befindlichkeits-Skala BBS),
which consists of 16 bipolar items (a choice between
two properties, such as tired/awake) will be used for this
study. The instrument, which covers four domains (vital-
ity, balance, extraversion, and vigilance), is well estab-
lished, validated, and suitable for Swiss and German
populations (the scale was developed in Switzerland)
[13]. Patients will be asked to fill in the form on the
afternoon of the second and fourth day after surgery
(during treatment versus after treatment).
Caffeine-related side effects
Patients will receive a self-administered questionnaire
concerning the potential side effects of caffeine together
with the well-being questionnaire mentioned above (i.e.,
on days 2 and 4). No established or validated instrument
could be found for this purpose. Thus, the questionnaire
was adopted from Liguori et al. [14] and complemented
with questions regarding sleep and the patient’s self-
assessment on whether the patient actually received
caffeine. In addition, the established and validated
Leeds sleep-evaluation questionnaire will be adminis-
tered [15–17].
Consumption of sleep-inducing drugs
The type and amount of sleep-inducing drugs will be
taken from the medical records.
Satisfaction with surgery
On day 4 (or before release), patients will be asked about
satisfaction with the surgery. They can rate their satisfac-
tion on a seven-step Likert scale (extremely unsatisfied
to extremely satisfied).
Ethics
This clinical study will be conducted in accordance with
the current version of the World Medical Association
Declaration of Helsinki, ICH-GCP, and the currently
valid local regulations. The current version of the study
protocol (Version 3 from 14 August 2015) has been
approved by the Ethics Committee of the Canton St.
Gallen (EKSG 15-023) and by Swissmedic (Swiss Agency
for Therapeutic Products, www.swissmedic.ch). Patients
will be informed verbally by an investigator about the
aims, the design, the risks, the patient rights, and the
course of the trial. They will also receive printed patient
information. Only patients who have signed the informed
consent form 24 h before surgery and meet all inclusion
and exclusion criteria will be included in the trial.
Study outline
If a suitable patient is identified during the outpatient
visit in preparation of surgery, he or she will be informed
about the trial by a surgeon or physician. If the patient is
interested in participation, the course of the trial will be
explained in detail to the patient, and the investigator
inquires whether all inclusion and exclusion criteria are
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met. If this is the case, the patient will receive a printed
version of the patient information and the informed con-
sent form. The informed consent form has to be signed
and returned no later than on the day before surgery.
After surgery, the inclusion criteria will be checked
again (no change in the planned course of surgery), and
if all criteria are fulfilled, the patient will be randomized
to receive capsules containing either 100 mg caffeine,
200 mg caffeine, or placebo (corn starch) (Fig. 1).
If the wound dressing was placed before 1 p.m., the
first capsule will be given in the evening; otherwise, in
the morning of the following day. Patients will take a
total of ten capsules, one with each meal (three times
daily). However, the medication will be stopped after the
primary endpoint (normal bowel movement) has been
reached. The remaining capsules will be returned to the
study center. A placard will be attached to the patient
bed to indicate study participation and that the patient
is not allowed to consume caffeine-containing beverages
or food.
In addition to the study treatment, the patients will
take a capsule with radiopaque markers every morning
starting with the day after surgery for 3 days. On day 4
after surgery, a patient will undergo X-ray imaging to
determine the location of the markers to determine
the colonic passage time.
Otherwise, the treatment will not differ from the treat-
ment of the colectomy received outside of the study, in-
cluding the treatment of an ileus after the end of the
study period. In case of an ileus after the patient has
taken the last study medication, the underlying medical
conditions will be corrected, in particular, electrolyte or
acid-base abnormalities. Patients suffering from vomit-
ing or distention will receive a nasogastric tube. Finally,
patients with an ileus will receive laxatives (magnesium
salts, Laxoberon, and one enema/day) and prokinetic
drugs (erythromycin 3 × 100 mg/day i.v. for 3 days, and
12–24 h later, metoclopramide 10–30 mg/day iv, together
with neostigmine 0.5–1.5 mg iv).
Randomization and blinding
Randomization will occur after surgery and inclusion/
exclusion criteria have been met. Each patient is assigned
with equal probability to one of three treatment arms
based on a permuted block randomized list with variable
block sizes of three to 15. After 60 patients (at the interim
analysis) have been enrolled, the patients will be equally
allocated to the three arms. The Cantonal Pharmacy of
Zurich prepares the study medication based on this
randomization list and packages the medication in indis-
tinguishable containers labelled with consecutive numbers
(1–180), according to the list. Medication consists of cap-
sules of the same appearance and level of filling (corn
starch was added to the capsules containing the caffeine
to assure equal filling of all capsules).
For the first 20 patients, medications will be assigned
in the order of surgery. After 20 patients, the second site
(Rorschach) will be activated for recruiting. Batches of
medications with consecutive numbers (according to
demand, approximately 5–10) will be transferred to
the second site. Each site will then assign the medication
according to the lowest available medication number at
the site.
Except for the study coordinator (who generated the
randomization list) and the Cantonal Pharmacy, no one
has access to the randomization list or has knowledge of
the allocation sequence (the study coordinator keeps a
password-encrypted and protected copy). Thus, neither
the study participant nor the investigator or nursing staff
have knowledge of the treatment assignment. In addition,
the statistician will analyze the data while blinded to the
treatment allocation (treatment arms will be coded with
A, B, and C).
In case of unforeseen adverse events that require a
knowledge of the treatment allocation, an emergency
unblinding procedure is available: an envelope corre-
sponding to the medication number will be added to the
patient file of each study participant. This envelope con-
tains a 12-character code (numerals and case sensitive
Fig. 1 Time course of the study treatment. Study treatment starts the evening of surgery if wound dressing was applied before 1 p.m.; otherwise,
in the morning of the next day. Study treatment continues until the first solid bowel movement or until ten capsules have been taken
(whichever occurs first). The dotted line at both ends of the study treatment period indicates that the start and end of the study
treatment can vary according to the above-stated rules
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letters) specific for each medication number. The medi-
cation number and the code can be entered in a gener-
ally accessible program, which then will reveal the
treatment assignment. Any surgeon of the department
can perform this procedure; however, the surgeon will
be asked to give a reason for unblinding. The user name
and the computer ID, as well as the time of unblinding,
will be recorded, and a message will be sent to the study
coordinator.
Technically, the 12-character code is a random key
phrase to decode the AES encoded treatment assign-
ment stored in the program. Thus, neither the code in
the envelope nor the (encrypted) data in the program
alone can be used to derive the treatment assignment.
Only the medication number-specific combination of
the code in the envelope together with the encrypted
data in the program will allow unblinding of the given
medication number.
Statistical analysis
One interim analysis is planned to assess the primary
outcome and the safety of the treatment after 60 patients
have been randomized. The statistician will provide an
analysis of the primary outcome and a summary of ad-
verse events (in particular, adverse events attributable to
caffeine). In this analysis, the arm assignments will not
be revealed (blinded); the arms are only labeled A, B,
and C. The results will be presented to the data and
safety monitoring committee (DSMC). Based on these
data, the trial chairperson and the DSMC will decide
whether to continue the trial without modification, con-
tinue the trial with modification, or stop the trial due to
safety or efficacy concerns. If in doubt, the DSMC can
ask to reveal the arm assignments before making a final
decision. Early stopping of the trial for efficacy at the in-
terim analysis should only be instituted if the benefit of
the treatment is shown “beyond reasonable doubt.” A
nominal p-value < 0.0007 (O’Brien Fleming alpha spend-
ing, see below) provides guidance in this instance but is
not binding for this decision. No formal criteria for early
stopping for safety reasons will be instituted. The DSMC
will make this decision based on statistical analysis, as
well as on clinical judgment.
The results of the interim analysis will be confidential
and strictly limited to the trial statistician and the trial
chair and co-chairs, as well as the DSMC. This confiden-
tiality should prevent any bias by the interim results on
the continuation of the trial.
Statistical analysis will be performed with a current R
environment (www.r-project.org). For baseline charac-
teristics, descriptive statistics will be used as appropriate.
All confirmatory analyses will primarily be performed as
an intention-to-treat-analysis, assessing all patients with
available data for the outcomes according to the
randomization. The significance level alpha for analysis
of the primary outcome will be adjusted to the exact
proportion of information included in the interim analysis
if the analysis is not performed at exactly 60 enrolled pa-
tients. For all other analyses, two-sided significance tests
with an alpha of 0.05 will be applied.
To maintain the alpha level, an O’Brien Fleming alpha
spending function will be used [18]. The formal signifi-
cance level in the interim analysis after 60 enrolled
patients is alpha = 0.0007. The alpha for the final analysis
will be 0.0498 for the assessment of the time to first
bowel movement in the main analysis.
For the final analysis, the superiority of caffeine over
placebo for the time to first bowel movement (primary
outcome) will be assessed irrespective of the caffeine
dosage using a Mann-Whitney-U-statistic. Hence, the
arms with 100 mg and 200 mg caffeine will be treated as
one arm. To maintain the alpha level despite the interim
analysis, the alpha for testing the hypothesis is 0.0498.
Secondary continuous outcomes will be assessed by
regression analysis of the mean ranks considering the
caffeine dosage. Colon transit time analysis will be per-
formed while additionally stratified by gender, as colon
transit time is significantly shorter in men. Categorical
secondary outcomes will be assessed by logistic regression
analysis considering the caffeine dosage. Final analysis will
be done according to the intention-to-treat principle and
compared to per-protocol analyses. Auxiliary nonconfir-
matory analyses will be performed to assess the influence
of baseline and treatment characteristics on the primary
and secondary outcomes.
Sample size calculation
Sample size calculation was performed for the main
outcome, the time to first bowel movement using the
R environment version 3.0, and the “gsDesign” and
“samplesize” packages.
In a previous study, coffee consumption reduced the
time to bowel movement after surgery from 74 ± 21 h to
60 ± 21 h (mean ± standard deviation) [10]. In that study,
one cup of coffee (containing 80 to 130 mg of caffeine
[19]) was administered three times a day. The published
results of this study were based on a mix of open and
laparoscopic procedures in patients with and without
epidural analgesia. Because we have access to the raw
data of this study, possible bias by the type of surgical
access and epidural analgesia could be eliminated. Using
the raw data (per-protocol analysis), the time to first
bowel movement for patients after open colon resection
with epidural analgesia was 61.5 ± 18.5 h for the 21
patients receiving coffee versus 72.5 ± 19.5 h for the 25
patients receiving the placebo. The number of patients
with laparoscopic surgery was too low to derive mean-
ingful data. The standardized effect size of caffeine was
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estimated to be 0.5 (a reduction of 10 h with a standard
deviation of 20 h). Even if the absolute time to bowel
movement after laparoscopic colectomy differs from the
time after open surgery, the standardized effect size for
both types of access can be assumed comparable. In
addition, a standardized effect size of 0.5 is usually con-
sidered to be of clinical importance for study outcomes.
Assuming a power of 80 % with a two-sided alpha of
0.05 (hypothesis: superiority of caffeine), a total of 144
patients (N = 48 in the placebo, and N = 96 in the treat-
ment arms) are necessary to detect a standardized effect
size of 0.5 for a 1:2 ratio of placebo versus caffeine (for
this analysis, the two caffeine arms (100 mg/200 mg) are
pooled). Assuming a 20 % dropout rate (withdrawal
rate), 180 patients are required for the study. Patients
who withdraw from the study before receiving the first
study treatment (caffeine, placebo, or radio-opaque
markers) will be replaced by other patients. Otherwise no
replacement for dropout or withdrawals will be performed.
A bootstrap simulation using the raw data mentioned above
confirmed the parametrically determined sample size.
Data collection and monitoring
Patients will be hospitalized during the whole study (due
to the colectomy). Thus, study participants are under
steady monitoring by surgeons and regular nursing staff.
Furthermore, a dedicated study nurse will collect data
from the patients’ records and will ask the patients directly
for the key endpoints (time to first flatus, time to bowel
movement, etc.). This study nurse will also deliver and
collect the questionnaires from the patients and will help
them with the questionnaires if the patient so wishes.
Data will be collected with a custom-made software
with extensive data-entry checks (numerical data are
restricted to plausible ranges, and categorical data entry
is performed via pull-down menus or option buttons).
Entry forms for questionnaires have the same layout as
the questionnaires themselves. Thus, correct data entry
can be confirmed by simple pattern comparison. Data
entry is recorded in an audit log, the data set can be
restored to the state of the last five close events, and an
overnight backup to a remote server is performed daily.
Patient safety
Since patients are hospitalized during the whole study
period, they are well monitored and adverse events can
be quickly treated. Most people in the Western world
consume caffeine-containing beverages on a regular
basis. The lower dose of caffeine used in this study
(100 mg) corresponds to approximately 1 cup of filtered
coffee. Furthermore, numerous medications contain caf-
feine as an additional ingredient (e.g., painkillers); thus,
one can assume that the consumption of caffeine, even
at the higher dose of 3 × 200 mg is very safe for the
patients. However, few data exist on the effect of caffeine
on elderly (most patients presumably will be older than
50 years) [20, 21], and none, on the consumption right
after abdominal surgery.
Most of the documented side effects are not very
severe and are usually observed after higher dosages.
Documented side effects are muscle tremor (>200 mg),
sleeplessness, restlessness, headache (>200 mg), irritabil-
ity, gastrointestinal complaints, tachycardia, and, in rare
cases, allergic reactions. Doses of 100 mg are not recom-
mended in the case of tachyarrhythmia and liver cirrho-
sis. All these side effects and restrictions have been
considered in the exclusion criteria [22].
While all available knowledge suggests that the con-
sumption of caffeine after surgery should be safe, unex-
pected adverse effects cannot be ruled out with certainty.
In case a patient should be harmed by the trial treatment,
the sponsor obtained a liability insurance to cover any
damages caused by the trial participation (as required by
Swiss law).
The safety and efficacy of the study treatment is being
monitored by a data and safety monitoring committee
consisting of three members who are independent of the
study. The members are specialists in hepatology, emer-
gency medicine, and surgery.
Publication
The results of this trial are intended for publication in a
peer-reviewed medical journal independently of the out-
come of the trial. Trial participants will be provided with
a German summary of the trial results or a copy of the
final publication if they expressed their interest on the
informed consent form to receive one or both of these
documents.
Discussion
A previous study showed that postoperative coffee con-
sumption shortens the time to first bowel movement
after colorectal resections [10]. As outlined in the Back-
ground section, it is highly unlikely that this effect is due
to the physical properties (temperature, osmolality, or
volume) of the coffee. Much more likely, one (or more)
of the numerous phytochemicals of the coffee bean are
responsible for the effect. The most obvious candidate
seems to be caffeine, the most popular and probably
best-researched component of the coffee. However, very
little evidence exists that caffeine was responsible for the
observed effect in the study by Müller et al. [10]. Rao et
al. reported that the effect of caffeinated coffee on
colonic function is stronger than decaffeinated coffee;
however, even decaffeinated coffee had an effect on the
colonic function [9]. Whether this effect was due to the
low amount of caffeine still present in the decaffeinated
coffee or due to another substance is unknown. Thus,
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we agree that our hypothesis for this trial is rather
speculative. Nevertheless, the safety profile of caffeine is
well documented, and the substance is part of the daily
diet of most people in the Western world. In case our
study hypothesis should be wrong, the risk of doing
harm to the study participants is extremely low. Therefore,
we think this study is ethically acceptable, particularly con-
sidering that, if the hypothesis were proven, a cost-effective
and well-accepted drug with little side effects would be
available to ameliorate postoperative bowel paralysis.
Trial status
Since 1 August 2015, the trial is open for recruiting, and
so far, 12 patients have been randomized (as of 7 March
2016).
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